Satellos Bioscience Inc. (MSCL.TO) Research

Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.

Market snapshot

Symbol
MSCL.TO
Price
$8.15
Day change
+0.25%
Market cap
$63.2M
P/E ratio
-1.76x
52-week range
6.36-18.98
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cardiol Therapeutics Inc. (CRDL.TO)
  • Cybin Inc. (CYBN.NE)
  • Grown Rogue International Inc. (GRIN.CN)
  • Helix BioPharma Corp. (HBP.TO)
  • Cannara Biotech Inc. (LOVE.V)
  • Medicenna Therapeutics Corp. (MDNA.TO)
  • Quipt Home Medical Corp. (QIPT.TO)
  • BioSyent Inc. (RX.V)

Open Satellos Bioscience Inc. (MSCL.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.